Proteases and protease inhibitors

• US 20050260708A1
• Filed: 03/04/2005
• Published: 11/24/2005
• Est. Priority Date: 08/09/1999
• Status: Abandoned Application

• Current Assignee: Incyte Corporation
• Original Assignee: Incyte Corporation
• Inventors: Baughn, Mariah R., Lal, Preeti, Yue, Henry, Tang, Y. Tom, Bandman, Olga, Lu, Dyung Aina M., Yang, Junming, Azimzai, Yalda
• Application Number:
  US11/071,580
• Publication Number:
  US 20050260708A1
• Time in Patent Office: Days
• US Class Current: 435/69.100
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/81 Protease inhibitors
• CPC Class Codes: C12N 9/48 acting on peptide bonds (3.4)
• CPC Class Codes: C12N 9/6421 from mammals

Abstract

The invention provides human proteases and protease inhibitors (PPIM) and polynucleotides which identify and encode PPIM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of PPIM.

Claims

1-28. -28. (canceled)

29. An isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising an amino acid sequence of SEQ ID NO;

1;

(b) a biologically active fragment of the polypeptide of (a); and

(c) an immunogenic fragment of the polypeptide of (a).

30. An isolated polypeptide of claim 29 consisting of the polypeptide of (a).

31. An isolated polypeptide of claim 29 consisting of a biologically active fragment of the polypeptide of (a).

32. An isolated polypeptide of claim 29 consisting of an immunogenic fragment of the polypeptide of (a).

33. An isolated polypeptide of claim 29 encoded by a polynucleotide selected from the group consisting of:

(i) a polynucleotide comprising a polynucleotide sequence of SEQ ID NO;

2;

(ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to SEQ ID NO;

2;

(iii) a polynucleotide comprising a portion of the polynucleotide sequence of SEQ ID NO;

2 that specifically identifies SEQ ID NO;

2.

(iv) a polynucleotide comprising a polynucleotide complementary to the polynucleotide of (i), (ii), or (iii);

(v) an RNA equivalent of the polynucleotide of (i), (ii), (iii) or (iv);

(vi) a polynucleotide of (i), (ii) or (iii) further comprising a promoter sequence operably linked to said polynucleotide of (i), (ii) or (iii).

34. An isolated polypeptide of claim 29 produced recombinantly.

35. An isolated polypeptide of claim 33 produced by culturing a cell transformed with a polynucleotide of (iv) under conditions suitable for expression of the polypeptide, and recovering the polypeptide so expressed.

36. An isolated antibody that specifically binds to a polypeptide of claim 29.

37. An isolated antibody of claim 36, wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single chain antibody, a Fab fragment, a F(ab′

)₂ fragment, and a humanized antibody.

38. An isolated antibody of claim 36, wherein said antibody is selected by screening a recombinant immunoglobulin library.

39. An isolated antibody of claim 37, wherein said antibody is selected by screening a Fab expression library.

40. An isolated antibody that specifically binds to a polypeptide of claim 33.

41. An isolated antibody of claim 40, wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single chain antibody, a Fab fragment, a F(ab′

)₂ fragment, and a humanized antibody.

42. An isolated antibody of claim 40, wherein said antibody is selected by screening a recombinant immunoglobulin library.

43. An isolated antibody of claim 40, wherein said antibody is selected by screening a Fab expression library.

44. A method of detecting a polypeptide of interest in a sample, comprising:

incubating the sample with an antibody that specifically binds to a polypeptide of claim 29 under conditions suitable for binding of the antibody to the polypeptide of interest if present in the sample; and

detecting biding of the polypeptide of interest to the antibody, wherein binding indicates the presence or amount of the polypeptide of interest in the sample.

45. A method of claim 44, wherein the sample is a body fluid sample from a human.

46. An isolated polynucleotide selected from the group consisting of:

(i) a polynucleotide comprising a polynucleotide sequence of SEQ ID NO;

2;

(ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to SEQ ID NO;

2;

(iii) a polynucleotide comprising a portion of the polynucleotide sequence of SEQ ID NO;

2 that specifically identifies SEQ ID NO;

2.

(iv) a polynucleotide comprising a polynucleotide complementary to the polynucleotide of (i), (ii), or (iii);

(v) an RNA equivalent of the polynucleotide of (i), (ii), (iii) or (iv);

(vi) a polynucleotide of (i), (ii) or (iii) further comprising a promoter sequence operably linked to said polynucleotide of (i), (ii) or (iii).